Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial (SMART_MS)
Primary Purpose
Multiple Sclerosis
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
SMART
Sham brain training (Sudoku)
Sponsored by

About this trial
This is an interventional treatment trial for Multiple Sclerosis
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of MS, received ≥3-months pre-enrolment (allowing for acute adjustment, as per other trials of cognitive rehabilitation)
- Age 18-89 (to meet the standardisation criteria of psychometric assessments)
- Cognitive difficulties as assessed by Perceived Deficits Questionnaire (PDQ) self-report (≥27) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) testing (≤1 standard deviation below normative reference-value)
- Able to read and speak English to standard necessary for completing assessment and intervention procedures
- Able and willing to access a computer/tablet/smart-phone with internet connection throughout the study
- Able and willing to give informed consent
Exclusion Criteria:
- Currently receiving cognitive rehabilitation
- Previously received SMART training
- Vision or hearing problems precluding completion of procedures
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Sham Comparator
No Intervention
Arm Label
TAU + SMART
TAU + Sham training
TAU (treatment-as-usual)
Arm Description
Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)
Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention
Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
Outcomes
Primary Outcome Measures
Recruitment and retention rates
Numbers eligible/interested/consented and randomised (and reasons for non-participation), number completing baseline and outcome assessments at Follow-up 1
Completion rates of outcome measures
Missing response-data
Intervention drop-out rate
Numbers in the intervention condition that drop out (complete <6 sessions) and reasons for intervention non-completion
Secondary Outcome Measures
Full Information
NCT ID
NCT04975685
First Posted
July 1, 2021
Last Updated
July 14, 2021
Sponsor
University of Lincoln
Collaborators
University of Exeter, Nottinghamshire Healthcare NHS Trust, National University of Ireland, Maynooth, University of Nottingham
1. Study Identification
Unique Protocol Identification Number
NCT04975685
Brief Title
Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial
Acronym
SMART_MS
Official Title
Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2021 (Anticipated)
Primary Completion Date
April 30, 2023 (Anticipated)
Study Completion Date
April 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Lincoln
Collaborators
University of Exeter, Nottinghamshire Healthcare NHS Trust, National University of Ireland, Maynooth, University of Nottingham
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Background: Multiple Sclerosis (MS) is a chronic condition of the central nervous system; around 1 in 600 people in the United Kingdom have MS. Many people with MS (70%) have cognitive difficulties, which they experience as distressing and disabling, and there is currently a lack of treatment options to improve these difficulties.
SMART (Strengthening Mental Abilities with Relational Training) - a theory-based online cognitive training programme, which has been shown to improve general cognitive abilities - has not been tested with people who have MS.
Aims: To conduct a feasibility study to inform development of a definitive trial of SMART for improving cognitive functioning in people with MS. The investigators will assess:
Acceptability to participants of the intervention, delivery format, inclusion/exclusion criteria, baseline and outcome measures, randomisation protocol, and study procedures
The framework for a cost-effectiveness analysis alongside a definitive trial
Participant recruitment and retention rates
Sample-size needed for fully powered trial
Signal of efficacy
Plan: To address Aims 1-5, the investigators will recruit 60 adults with MS who are experiencing cognitive difficulties, identified from MS clinics.
Participants will complete baseline assessments of their cognitive abilities and answer questionnaires about their cognitive difficulties, personal priorities, mood, fatigue, self-efficacy, quality of life, and healthcare services used.
Assessments will be administered by a researcher, face-to-face or remotely.
Participants will be randomly allocated to one of three arms (20 per group):
Group 1: Receives SMART intervention online - plus usual care (MS Nurse support). SMART intervention involves completing a series of logic problems, which are designed to train skills that scaffold complex cognition.
Group 2: Receives usual care alone. Group 3: Receives a 'control' intervention online - plus usual care.
Baseline measures will be re-administered at three- and six-months post-randomisation. Researchers and patient-partners (people with personal experience of MS, who will act as co-researchers) will also interview 30 participants about their experience of the study and treatment. All qualitative data will be transcribed and thematically analysed in terms of a priori feasibility aims. Quantitative data will enable sample-size calculation for a definitive study and determine signal of efficacy.
Detailed Description
Background:
Cognitive deficits have been identified as the most debilitating impact of MS. These deficits interfere with daily living, manifesting as inattention (e.g., getting easily distracted), forgetting (e.g., leaving the stove on after cooking), and problem-solving difficulties (e.g., getting confused when completing a multi-stage task like cooking). The burden of these deficits reduces quality of life and restricts daily activities and employment - and correspondingly, diminishes patient perceptions of personal competence and self-worth. Cognitive rehabilitation is not routinely offered in the National Health Service (NHS) - and, when it is offered, largely focuses on teaching people to compensate for deficits (e.g., using external memory aids) rather than retraining cognitive skills. A recent state-of-the-field review from international MS experts has called for research towards identifying effective, evidence-based, and clinically feasible interventions to address cognitive deficits in MS. There is evident uncertainty about how to intervene effectively, and this is recognised by the James Lind Alliance as a top-10 priority area for research-funding.
Our trial tests the feasibility of a highly accessible and low-resource format of cognitive rehabilitation (online training). Given NHS resource constraints, the scale of the problem, and concerns about face-to-face consultation in the context of COVID-19, new and cost-effective ways of implementing promising cognitive rehabilitation interventions are needed. Low-resource online formats are more likely to be implemented if found to be clinically effective, enable wider access for patients, and provide active support for self-management - consistent with (1) models of care for managing longer-term conditions and (2) the digital healthcare agenda.
As a feasibility trial, outcomes are unlikely to immediately effect changes to NHS practice. However, this is a necessary step towards developing a definitive trial - and will give us a signal of efficacy, a prerequisite for progression to a definitive trial. If found to be clinically- and cost-effective, the latter trial could create a step-change in MS cognitive rehabilitation - improving service-delivery and optimising support with limited additional resources.
Aim:
To conduct a feasibility study to inform development of a definitive trial of SMART (an online 'brain training' treatment) for improving cognitive functioning in people with MS.
The investigators will assess:
Acceptability to participants of the intervention, delivery format, inclusion/exclusion criteria, baseline and outcome measures, randomisation protocol, and study procedures
The framework for a cost-effectiveness analysis alongside a definitive trial
Participant recruitment and retention rates
Sample-size needed for fully powered trial
Signal of efficacy
Research plan:
The investigators will conduct a three-arm feasibility Randomised Controlled Trial (RCT) comparing (1) SMART + treatment-as-usual (TAU) with (2) TAU and (3) active control ('sham') training + TAU.
Consenting eligible patients will complete a baseline cognitive assessment battery and questionnaires assessing impact of living with MS, health-related quality of life, subjective cognitive difficulties, and service/resource-use.
After completing baseline assessments, participants will be randomly allocated to one of three arms (using minimisation to balance participant characteristics across arms):
SMART + TAU
TAU. Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
Sham training (active control: Sudoku) + TAU. The investigators selected Sudoku to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials. Sham-training will be delivered online, over the same timeframe/regimen as SMART treatment, and with telephone support to facilitate access - controlling for modality, schedule of engagement, and relational support.
A Research Fellow will complete blinded outcomes at 3- and 6-months post-randomisation, by re-administering baseline measures. Quantitative data will enable sample-size calculation for a definitive study and determine signal of efficacy. After the first follow-up assessment (>3 months post-randomisation) a sub-sample of participants will engage in feasibility-feedback interviews.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TAU + SMART
Arm Type
Experimental
Arm Description
Participants in this arm will receive treatment-as-usual (TAU) plus the experimental SMART intervention (theory-based cognitive training)
Arm Title
TAU + Sham training
Arm Type
Sham Comparator
Arm Description
Participants in this arm will receive treatment-as-usual (TAU) plus a control (sham) cognitive training intervention
Arm Title
TAU (treatment-as-usual)
Arm Type
No Intervention
Arm Description
Participants in this arm will receive treatment-as-usual (TAU). Content of TAU for cognitive concerns, based on our clinical experience and knowledge, is often informational support from an MS Nurse with signposting to the MS Society/MS Trust websites.
Intervention Type
Behavioral
Intervention Name(s)
SMART
Intervention Description
SMART (Strengthening Mental Abilities Through Relational Training) is a web-based cognitive training program that directly trains 'relational skills' - skills necessary to understand how concepts relate to one another, which underpin complex cognition.
Intervention Type
Behavioral
Intervention Name(s)
Sham brain training (Sudoku)
Intervention Description
Sudoku was selected to control for expectancy effects based on popular conceptions that it broadly improves cognitive functions, coupled with little evidence supporting this notion, and its use as an active control in similar trials.
Primary Outcome Measure Information:
Title
Recruitment and retention rates
Description
Numbers eligible/interested/consented and randomised (and reasons for non-participation), number completing baseline and outcome assessments at Follow-up 1
Time Frame
16 months
Title
Completion rates of outcome measures
Description
Missing response-data
Time Frame
6 months
Title
Intervention drop-out rate
Description
Numbers in the intervention condition that drop out (complete <6 sessions) and reasons for intervention non-completion
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
Perceived Deficits Questionnaire (PDQ)
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
Symbol Digit Modalities Test (SDMT)
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
Generalized Anxiety Disorder Scale-7 (GAD-7)
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
Patient Health Questionnaire-9 (PHQ-9)
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
Modified Fatigue Impact Scale-5-Item (MFIS-5)
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
Personal Questionnaire (PQ)
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
EQ-5D-5L
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
MS Impact Scale-29 (MSIS-29)
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
Title
ICECAP-A
Description
Estimates of (group-level) effect-sizes with 95% Confidence Intervals (CIs) and proportions achieving reliable/clinically significant change (exploring signal of efficacy)
Time Frame
Change between baseline and 3-month follow-up. Additional follow-up at 6 months.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of MS, received ≥3-months pre-enrolment (allowing for acute adjustment, as per other trials of cognitive rehabilitation)
Age 18-89 (to meet the standardisation criteria of psychometric assessments)
Cognitive difficulties as assessed by Perceived Deficits Questionnaire (PDQ) self-report (≥27) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) testing (≤1 standard deviation below normative reference-value)
Able to read and speak English to standard necessary for completing assessment and intervention procedures
Able and willing to access a computer/tablet/smart-phone with internet connection throughout the study
Able and willing to give informed consent
Exclusion Criteria:
Currently receiving cognitive rehabilitation
Previously received SMART training
Vision or hearing problems precluding completion of procedures
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
36056385
Citation
Golijani-Moghaddam N, Dawson DL, Evangelou N, Turton J, Hawton A, Law GR, Roche B, Rowan E, Burge R, Frost AC, das Nair R. Strengthening Mental Abilities with Relational Training (SMART) in multiple sclerosis (MS): study protocol for a feasibility randomised controlled trial. Pilot Feasibility Stud. 2022 Sep 3;8(1):195. doi: 10.1186/s40814-022-01152-7.
Results Reference
derived
Learn more about this trial
Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial
We'll reach out to this number within 24 hrs